Express News | FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (Sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With Egfr Mutations
Merck & Co Unusual Options Activity For December 02
Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Cuts Target Price to $110
Bernstein Trims Price Target on Merck to $110 From $115
Merck (MRK.US) antibiotic combination approved for market launch in China
Merck (MRK.US) antibiotic combination approved for market launch in China.
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings